JP2024520577A - 抗ｎｋｇ２ａ抗体及び組成物 - Google Patents

抗ｎｋｇ２ａ抗体及び組成物 Download PDF

Info

Publication number
JP2024520577A
JP2024520577A JP2023573662A JP2023573662A JP2024520577A JP 2024520577 A JP2024520577 A JP 2024520577A JP 2023573662 A JP2023573662 A JP 2023573662A JP 2023573662 A JP2023573662 A JP 2023573662A JP 2024520577 A JP2024520577 A JP 2024520577A
Authority
JP
Japan
Prior art keywords
amino acid
seq
antibody
nos
nkg2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520577A5 (https=
Inventor
ハンセン，ランディ・ウェスト
ウーレンブロック，フランチスカ・カタリーナ
ディートリッヒ，ニコライ
ウォルソー，アンネ
グランダル，ミカエル・モンラード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of JP2024520577A publication Critical patent/JP2024520577A/ja
Publication of JP2024520577A5 publication Critical patent/JP2024520577A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023573662A 2021-06-01 2022-05-31 抗ｎｋｇ２ａ抗体及び組成物 Pending JP2024520577A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195470P 2021-06-01 2021-06-01
US63/195,470 2021-06-01
PCT/EP2022/064703 WO2022253805A1 (en) 2021-06-01 2022-05-31 Anti-nkg2a antibodies and compositions

Publications (2)

Publication Number Publication Date
JP2024520577A true JP2024520577A (ja) 2024-05-24
JP2024520577A5 JP2024520577A5 (https=) 2025-06-06

Family

ID=82117230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573662A Pending JP2024520577A (ja) 2021-06-01 2022-05-31 抗ｎｋｇ２ａ抗体及び組成物

Country Status (17)

Country Link
US (2) US12012450B2 (https=)
EP (1) EP4347651A1 (https=)
JP (1) JP2024520577A (https=)
KR (1) KR20240016991A (https=)
CN (1) CN117460748A (https=)
AR (1) AR126001A1 (https=)
AU (1) AU2022286617A1 (https=)
BR (1) BR112023024772A2 (https=)
CA (1) CA3222040A1 (https=)
CL (1) CL2023003562A1 (https=)
CO (1) CO2023015982A2 (https=)
IL (1) IL308695A (https=)
MX (1) MX2023014320A (https=)
PE (1) PE20240372A1 (https=)
PH (1) PH12023553123A1 (https=)
TW (1) TW202313683A (https=)
WO (1) WO2022253805A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140820A1 (zh) * 2022-12-28 2024-07-04 浙江博锐生物制药有限公司 抗nkg2a抗体及其用途
WO2024260280A1 (en) * 2023-06-21 2024-12-26 Elpiscience (Suzhou) Biopharma, Ltd. Antibodies or antigen-binding fragments binding to nkg2a and uses thereof
CN121941711A (zh) * 2024-02-08 2026-04-28 翰思艾泰生物医药科技(武汉)股份有限公司 Nkg2a/cd94靶向抗体及其用途
CN121108342B (zh) * 2025-09-08 2026-03-03 北京明璨生物科技有限公司 包含抗体和nk细胞的组合物在治疗癌症中的用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280945A1 (en) * 2006-06-02 2007-12-06 Sean Stevens High affinity antibodies to human IL-6 receptor
JP2011510047A (ja) * 2008-01-24 2011-03-31 ノボ・ノルデイスク・エー／エス ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
JP2017537069A (ja) * 2014-10-23 2017-12-14 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 抗ｎｋｇ２ａ剤を用いた癌の処置
JP2017538660A (ja) * 2014-09-16 2017-12-28 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 抗ｎｋｇ２ａ抗体を使用した治療計画
JP2019519199A (ja) * 2016-04-12 2019-07-11 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｔｉｍ−３抗体および組成物
WO2020094071A1 (zh) * 2018-11-07 2020-05-14 上海怀越生物科技有限公司 Nkg2a抗体及其制备方法和应用
WO2020102501A1 (en) * 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280945A1 (en) * 2006-06-02 2007-12-06 Sean Stevens High affinity antibodies to human IL-6 receptor
JP2011510047A (ja) * 2008-01-24 2011-03-31 ノボ・ノルデイスク・エー／エス ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
JP2017538660A (ja) * 2014-09-16 2017-12-28 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 抗ｎｋｇ２ａ抗体を使用した治療計画
JP2017537069A (ja) * 2014-10-23 2017-12-14 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 抗ｎｋｇ２ａ剤を用いた癌の処置
JP2019519199A (ja) * 2016-04-12 2019-07-11 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｔｉｍ−３抗体および組成物
WO2020094071A1 (zh) * 2018-11-07 2020-05-14 上海怀越生物科技有限公司 Nkg2a抗体及其制备方法和应用
WO2020102501A1 (en) * 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof

Also Published As

Publication number Publication date
US20220389100A1 (en) 2022-12-08
TW202313683A (zh) 2023-04-01
US12012450B2 (en) 2024-06-18
CN117460748A (zh) 2024-01-26
AU2022286617A1 (en) 2023-12-21
CO2023015982A2 (es) 2024-01-15
PE20240372A1 (es) 2024-03-05
EP4347651A1 (en) 2024-04-10
AR126001A1 (es) 2023-08-30
CA3222040A1 (en) 2022-12-08
WO2022253805A1 (en) 2022-12-08
KR20240016991A (ko) 2024-02-06
BR112023024772A2 (pt) 2024-02-15
MX2023014320A (es) 2023-12-13
PH12023553123A1 (en) 2024-03-04
IL308695A (en) 2024-01-01
CL2023003562A1 (es) 2024-07-12
US20240294638A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
JP7488323B2 (ja) 抗ｌａｇ－３抗体および組成物
TWI859319B (zh) 抗ｃｄ７３抗體及組合物
US12012450B2 (en) Anti-NKG2A antibodies and compositions
JP7679399B2 (ja) 抗ｆｌｔ３抗体及び組成物
US11807688B2 (en) Anti-AXL antibodies and compositions
US20210214454A1 (en) Anti-cd40 antibodies and compositions
RU2836004C1 (ru) Антитела и композиции против flt3
HK40106092A (zh) 抗nkg2a抗体和组合物
RU2837590C1 (ru) Антитела против axl и композиции
RU2837590C9 (ru) Антитела против axl и композиции
EA052808B1 (ru) Антитела и композиции против flt3
HK40081002A (en) Anti-axl antibodies and compositions
HK40084729A (en) Anti-flt3 antibodies and compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310